SPOTLIGHT: FDA demands delay Genzyme approval

Genzyme has been handed a letter from the FDA spelling out a new set of demands for data on Synvisc-One, a new version of its osteoarthritis drug that is dosed at twice a year. Genzyme says the agency's demands will delay an approval until the second half of next year. Report